Managers on a Mission: Med schools begin to quantify research, teaching, and patient care

Graphic: Leza Berardone The hallowed halls of medical academia may shudder at the thought of their denizens' life's work in research, teaching, and clinical care being reduced to numbers. But several administrators at the 125 medical schools in the United States feel they can implement a management system that measures outcomes in research, teaching effort, and clinical-work revenue/cost--and still preserve academic excellence. In fact, the system could bring, they say, some sorely needed acco

Written byKatherine Woodbury
| 7 min read

Register for free to listen to this article
Listen with Speechify
0:00
7:00
Share


Graphic: Leza Berardone
The hallowed halls of medical academia may shudder at the thought of their denizens' life's work in research, teaching, and clinical care being reduced to numbers.

But several administrators at the 125 medical schools in the United States feel they can implement a management system that measures outcomes in research, teaching effort, and clinical-work revenue/cost--and still preserve academic excellence. In fact, the system could bring, they say, some sorely needed accountability to their institutions.

Fiscal management has not been the strong suit of medical schools for many years, administrators say, and the bite managed care took out of a once-comfortable profit margin has exacerbated this situation.

"If tuition and state money are not sufficient for the educational mission, you have choices. You can raise tuition. You can go to the state. Or you say we're making profit on clinical [activities]--let's subsidize education. That's what happened in the ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies